<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36840949</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>378</StartPage><EndPage>386</EndPage><MedlinePgn>378-386</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27807</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">Higher urate levels are associated with improved ALS survival in retrospective studies, however whether raising urate levels confers a survival advantage is unknown. In the Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (SURE-ALS) trial, inosine raised serum urate and was safe and well-tolerated. The SURE-ALS2 trial was designed to assess longer term safety. Functional outcomes and a smartphone application were also explored.</AbstractText><AbstractText Label="METHODS">Participants were randomized 2:1 to inosine (n&#xa0;=&#xa0;14) or placebo (n&#xa0;=&#xa0;9) for 20&#x2009;weeks, titrated to serum urate of 7-8&#xa0;mg/dL. Primary outcomes were safety and tolerability. Functional outcomes were measured with the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R). Mobility and ALSFRS-R were also assessed by a smartphone application.</AbstractText><AbstractText Label="RESULTS">During inosine treatment, mean urate ranged 5.68-6.82&#x2009;mg/dL. Treatment-emergent adverse event (TEAE) incidence was similar between groups (p&#x2009;&gt;&#x2009;.10). Renal TEAEs occurred in three (21%) and hypertension in one (7%) of participants randomized to inosine. Inosine was tolerated in 71% of participants versus placebo 67%. Two participants (14%) in the inosine group experienced TEAEs deemed related to treatment (nephrolithiasis); one was a severe adverse event. Mean ALSFRS-R decline did not differ between groups (p&#xa0;=&#xa0;.69). Change in measured home time was similar between groups. Digital and in-clinic ALSFRS-R correlated well.</AbstractText><AbstractText Label="DISCUSSION">Inosine met pre-specified criteria for safety and tolerability. A functional benefit was not demonstrated in this trial designed for safety and tolerability. Findings suggested potential utility for a smartphone application in ALS clinical and research settings.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Muscle &amp; Nerve published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walk</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7941-1993</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Katharine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Locatelli</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Holy Cross Hospital, Fort Lauderdale, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macklin</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferment</LastName><ForeName>Valerie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manousakis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8309-9426</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chase</LastName><ForeName>Marianne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Connolly</LastName><ForeName>Mariah</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Research Organization, Barrow Neurological Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagostino</LastName><ForeName>Derek</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Research Organization, Barrow Neurological Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostrow</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pothier</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelevski</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Randall</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Research Organization, Barrow Neurological Institute, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherman</LastName><ForeName>Alexander V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinhart</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Daniela Grasso</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wills</LastName><ForeName>Anne-Marie</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarzschild</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, MassGeneral Institute for Neurodegenerative Disease, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beukenhorst</LastName><ForeName>Anna L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onnela</LastName><ForeName>Jukka-Pekka</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-7075-1681</Identifier><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0505-1168</Identifier><AffiliationInfo><Affiliation>Neurological Clinical Research Institute and Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>268B43MJ25</RegistryNumber><NameOfSubstance UI="D014527">Uric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>5A614L51CT</RegistryNumber><NameOfSubstance UI="D007288">Inosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014527" MajorTopicYN="N">Uric Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007288" MajorTopicYN="N">Inosine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">inosine</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">smartphone application</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>10</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>13</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36840949</ArticleId><ArticleId IdType="doi">10.1002/mus.27807</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Proctor P. Similar functions of uric acid and ascorbate in man? Nature. 1970;228(5274):868.</Citation></Reference><Reference><Citation>Yeum KJ, Russell RM, Krinsky NI, Aldini G. Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. Arch Biochem Biophys. 2004;430(1):97-103.</Citation></Reference><Reference><Citation>Fabbrini E, Serafini M, Colic Baric I, Hazen SL, Klein S. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes. 2014;63(3):976-981.</Citation></Reference><Reference><Citation>D'Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective of oxidative stress in sporadic ALS. Free Radical Biol Med. 2013;65:509-527.</Citation></Reference><Reference><Citation>Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4(11):600-609.</Citation></Reference><Reference><Citation>Chen X, Wu G, Schwarzschild MA. Urate in Parkinson's disease: more than a biomarker? Curr Neurol Neurosci Rep. 2012;12(4):367-375.</Citation></Reference><Reference><Citation>The Parkinson Study Group SURE-PD Investigators. Inosine to increase serum and CSF urate in Parkinson disease: a randomized, placebo-controlled trial. JAMA Neurol. 2014;71(2):141-150.</Citation></Reference><Reference><Citation>Paganoni S, Schwarzschild MA. Urate as a marker of risk and progression of neurodegenerative disease. Neurotherapeutics. 2017;14(1):148-153.</Citation></Reference><Reference><Citation>Paganoni S, Zhang M, Quiroz Z&#xe1;rate A, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012;259(9):123-128.</Citation></Reference><Reference><Citation>Chamorro A, Amaro S, Castellanos M, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol. 2014;13(5):453-460.</Citation></Reference><Reference><Citation>The Parkinson Study Group SURE-PD3 Investigators. Effect of urate-elevating inosine on early Parkinson disease progression: the SURE-PD3 randomized clinical trial. JAMA Neurology. 2021;326(10):926-939.</Citation></Reference><Reference><Citation>Nicholson K, Chan J, Macklin EA, et al. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2018;5(12):1522-1533.</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on motor neuron diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293-299.</Citation></Reference><Reference><Citation>Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999;18(11):1341-1354.</Citation></Reference><Reference><Citation>Berry JD, Miller R, Moore DH, et al. The combined assessment of function and survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3):162-168.</Citation></Reference><Reference><Citation>Torous J, Kiang MV, Lorme J, Onnela JP. New tools for new research in psychiatry: a scalable and customizable platform to empower data driven smartphone research. JMIR Ment Health. 2016;3(2):e16.</Citation></Reference><Reference><Citation>Berry JD, Paganoni S, Carlson K, et al. Design and results of a smartphone-based digital phenotyping study to quantify ALS progression. Ann Clin Transl Neurol. 2019;6(5):873-881.</Citation></Reference><Reference><Citation>Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716-723.</Citation></Reference><Reference><Citation>Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med. 2010;4(5):701-712.</Citation></Reference><Reference><Citation>Page A, Yung N, Auinger P, et al. A smartphone application as an exploratory endpoint in a phase 3 Parkinson's disease clinical trial: a pilot study. Digit Biomark. 2022;6:1-8.</Citation></Reference><Reference><Citation>Beukenhorst AL, Burke KM, Scheier Z, et al. Using smartphones to reduce research burden in a neurodegenerative population and assessing participant adherence: a randomized clinical trial and two observational studies. JMIR Mhealth Uhealth. 2022;10(2):e31877.</Citation></Reference><Reference><Citation>Rutkove S, Qi K, Shelton K, Liss J, Berisha V, Shefner JM. ALS longitudinal studies with frequent data collection at home: study design and baseline data. Amyotroph Lateral Scler Other Motor Neuron Disord. 2019;20:61-67.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>